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Abstract
Background: Post-transplant lymphoproliferative disorders (PTLD) are serious complications in lung transplant
recipients. No consensus on EBV DNAemia levels predictive of PTLD has been reached. In addition, in many
instances EBV DNAemia is determined in patients with suggestive symptoms only.
Methods: The characteristics of five patients with PTLD as well as the prevalence of EBV DNAmia in a cohort of
137 consecutive patients receiving lung transplantation are described.
Results: Twenty-six out of 137 patients (18.9%) were excluded from the analysis because lost at follow-up or dead
from PTLD-independent reasons within three months of transplantation. EBV DNA in peripheral blood mononuclear
cells (PBMC) was determined in 83/111 patients (74.8%) because of potential PTLD-related symptoms, while 28
patients (25.2%) showed no symptoms and were not examined. EBV DNAemia was positive in 53/83 patients
(63.8%), and negative in 30/83 patients (36.2%). PTLD was diagnosed in five (4.5%) patients at a median time of
270 (range 120-870) days following transplantation. All five PTLD (three large B-cell lymphomas, one Hodgkin
lymphoma and one possible pre-neoplastic lesion) were potentially associated with EBV infection. However, only 3/
5 patients with PTLD had detectable EBV DNAemia: < 1,000 copies EBV DNA/1 × 10
5 PBMC in one patient and >
1,000 copies EBV DNA/1 × 10
5 PBMC in two patients.
Conclusion: A systematic multidisciplinary (clinical, radiologic, virologic and histologic) approach is mandatory for
the diagnosis and management of PTLD in lung transplant recipients, while monitoring of symptomatic patients
only may provide an incomplete or late picture of the clinical problem. In addition, staining for EBV antigens and
quantification of EBV DNA in biopsy specimens should always be performed to understand the role of EBV
infection in the pathogenesis of PTLD.
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Background
Post-transplant lymphoproliferative disorders (PTLD)
represent serious infectious complications in lung trans-
plant recipients, who are at a greater risk than kidney,
heart and liver transplant recipients [1-3]. However, the
heterogeneous spectrum of clinical conditions included
in PTLD definition (ranging from polymorphic lympho-
proliferation to aggressive lymphomas) [3,4], the wide
time span from transplantation to emergence [2] and
the debated pathogenetic role of Epstein-Barr virus
(EBV) [2,4-6] make it difficult to perform cohort studies
in transplant recipients [1-8]. In particular, the wide
time interval to PTLD onset in different patient groups
affects the feasibility of a tight monitoring of EBV DNA
in blood, particularly in patients with late onset of
PTLD, such as solid organ transplant recipients. Thus,
systematic monitoring of EBV DNAemia in many trans-
plant centers is often impossible as it depends on clini-
cal manifestations suggestive of PTLD. For these
reasons, the role of detection and quantification of EBV
DNA in blood compartments (EBV DNAemia), used for
* Correspondence: f.baldanti@smatteo.pv.it
1Laboratori Sperimentali di Ricerca, Fondazione IRCCS Policlinico San Matteo,
27100 Pavia, Italy
Full list of author information is available at the end of the article
Baldanti et al. Virology Journal 2011, 8:421
http://www.virologyj.com/content/8/1/421
© 2011 Baldanti et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.monitoring patients at risk for PTLD [9-13] and guiding
preemptive treatment [9,14-16] is still debated.
Here we describe the characteristics of five patients
who developed PTLD and the prevalence of EBV
DNAemia in peripheral blood mononuclear cells
(PBMC) in a cohort of 137 consecutive patients sub-
mitted to lung transplantation in a single transplantation
center in Northern Italy from 2000-2007. Diagnosis and
treatment of this elusive disease remains a clinical
challenge.
Materials and methods
This retrospective study aimed at evaluating the preva-
lence and levels of EBV DNAemia in PBMC in a cohort
of patients submitted to single-lung, double-lung or
heart-lung transplantation in a single transplantation
center in Northern Italy from 2000 to 2007.
From 2000 to 2003, EBV DNAemia was determined
using a quantitative PCR technique [9], while from 2004
to 2007 a real-time PCR technique was adopted [17].
The two assays showed comparable sensitivity, being
both able to reproducibly detect 10 EBV DNA copies in
ab a c k g r o u n do f1×1 0
5 PBMC. In addition, the com-
parative analysis of a subset of PBMC samples as well as
the results of an international quality control program
QCMD http://www.qcmd.org showed agreement
between the two PCR assays for quantification of EBV
DNA levels (data not shown). Results were expressed as
EBV DNA copy number/1 × 10
5 PBMC, and samples
with no PCR signals were scored as containing < 10
EBV DNA copies/1 × 10
5 PBMC.
EBV DNAemia was prospectively determined when
the patient exhibited symptoms or signs potentially
associated with PTLD: fever of unknown origin, lym-
phoadenopathy, cytopenia, leukopenia, weight loss and
asthenia. A presumptive diagnosis of PTLD was made
based on virologic and radiologic findings and a defini-
tive diagnosis was made by histologic or cytologic exam-
ination of tissue biopsies or needle aspirates.
Immune suppression therapy was reduced in patients
showing EBV DNA values > 1,000 copies/1 × 10
5
PBMC [9]. Patients presenting with overt lymphomas
were submitted to standard treatment protocols.
All the patients signed an informed consent at the
time of transplantation. The study was approved by the
Internal Review Board (protocol no. P-20080013903, Jun
3, 2008). Due to the retrospective nature of the study
and the impossibility to obtain informed consent from
patients deceased and lost at follow-up, the IRB allowed
the analysis of anonymized stored samples and data
(IRB protocol no. P-20020001513, Jan 18, 2010).
The Shapiro-Wilk’s test was used to test the normal
distribution of quantitative variables. If they were nor-
mally distributed, mean and standard deviation (SD)
were used to summarize the results. Otherwise, median
and Interquartile range (IQR; 25° - 75° percentile) were
used. Specificity and sensitivity (with 95% Confidence
Intervals) were used to compare positive and negative
results. Differences between median EBV DNAemia
levels at first detection and at peak of infection were
evaluated with the Wilcoxon signed-rank test. The chi-
squared statistics or Fisher’s exact test, as appropriate,
were applied to compare qualitative variables. P < 0.05
was considered statistically significant. All tests were
two-sided. Data analysis was performed with the
STATA statistical package (vers: 9; Stata Corporation,
College Station, 2008, Texas, USA).
Results
Stored data of 137 patients receiving a single-lung (n =
58), double-lung (n = 74) or heart-lung (n = 5) trans-
plantation from January 2000 to June 2007 were retro-
spectively analyzed. Data have been prospectively
generated and archived as part of routine monitoring of
infectious complications in solid organs transplant reci-
pients. Ninety-nine patients (72.2%) were male, median
age at transplantation was 52 years (range 13-71).
Twenty-six out of 137 patients (18.9%) were excluded
from the analysis because lost at follow-up or dead from
PTLD-independent reasons within 3 months after trans-
plantation. The remaining 111 patients (81.1%) were
considered representative of the entire cohort, since no
differences in sex, age at transplantation, type of trans-
plantation and distribution of underlying diseases were
observed (p > 0.05 for all parameters).
Twenty-eight out of 111 patients (25.2%) never showed
symptoms suggestive of PTLD and were not examined
for EBV DNAemia, while 83 (74.8%) patients were exam-
ined at least once (median test no. 3; IQR 2 - 5) due to
the presence of potential PTLD-related symptoms.
EBV DNAemia was positive in 53/83 patients (63.8%),
while 30/83 patients (36.2%)w e r eE B VD N A - n e g a t i v e .
EBV DNAemia was first detected at a median time of
263 days from transplantation (IQR: 80 - 952). Among
the 53 EBV DNA-positive patients, 10 (18.8%) showed
EBV DNAemia levels > 1,000 copies/1 × 10
5 PBMC
(median 2,430; range 1,208-1,311,180), while 43 patients
showed lower values (median, 116; range 10-704).
Overall, PTLD was diagnosed in 5/111 (4.5%) patients
at a median time of 270 days after transplantation
(range 120-870) in the presence of different EBV DNA
levels in PBMC: 2 patients scored as EBV DNAemia
negative, 1 patient showed < 1,000 copies EBV DNA/1
×1 0
5 PBMC and 2 patients showed > 1,000 copies EBV
DNA/1 × 10
5 PBMC. Characteristics of the five patients
with PTLD are summarized in Table 1.
In more detail, Patient #1, developed primary EBV
infection two months after transplantation and low-level
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Twenty-five months after transplantation, EBV DNAe-
mia peaked at 1,420 copies/10
5 PBMC in the absence of
PTLD symptoms. Tapering of immune suppression was
associated with reduction of EBV DNAemia in PBMC
( F i g u r e1 ) .T h r e ea n dah a l fy e a r sp o s tt r a n s p l a n t a t i o n
the patient presented with laterocervical Hodgkin lym-
phoma (mixed cell) in the presence of 1,760 copies EBV
DNA/1 × 10
5 PBMC. Following multiple treatment
courses with interferon and anti-CD20 MAb, remission
of the lymphoma was achieved. In parallel, disappear-
ance of EBV DNA in blood was observed (Figure 1).
This patient died five years and eight months after
transplantation of bronchiolitis obliterans syndrome.
Patient #2 developed a broncho-mediastinic diffuse
large B-cell lymphoma eight months after transplanta-
tion. EBV DNA in PBMC was negative. The disease was
refractory to chemotherapy and the patient died eight
months later.
Patient #3, developed a diffuse large B-cell lymphoma
in the upper lobe of the transplanted lung associated
with homolateral hilar-mediastinic lymphadenopathy 11
months after transplantation. EBV DNAemia was nega-
tive. No remission was achieved despite chemotherapy
and the patient died three months later.
In patient #4, lung nodules suggestive of lymphoma
were detected by computerized tomography (CT) four
months after transplantation. Leukopenia (2,290 cells/μl)
associated with marked lymphopenia (8%) was simulta-
neously recorded. EBV DNAemia was positive at a low
level (183 copies/1 × 10
5 PBMC). One month later,
fever and asthenia prompted a second CT scan analysis
which revealed significant hilar bronchial and vascular
infiltrate of the left lung. Bronchoscopy showed extrinsic
occlusion of the major left bronchial lumen and conco-
mitant infiltrate of the bronchial wall. Histology con-
firmed the presence of a diffuse large B-cell lymphoma.
Immunohistochemistry documented the presence of
EBV antigens in more than 80% of neoplastic cells. EBV
DNAemia was still low (395 copies/1 × 10
5 PBMC).
Leukopenia (3,560 cells/μl) and lymphopenia (8%) still
persisted. Remission of the B-cell lymphoma was not
achieved following seven courses of chemotherapy. Two
years after transplantation, 19 copies EBV DNA/1 × 10
5
PBMC were shown in the presence of normal leukocyte
counts. The patient died three months later of a massive
hemophtysis.
In patient #5 a routine CT scan analysis performed
four months after transplantation showed a non-infiltra-
tive nodular lesion lacking contrast enhancement in the
left lower lobe. Positron emission tomography (PET)
analysis did not show increased glucose uptake in the
lesion, while two additional controlateral mediastinal
nodules showed increased glucose uptake. Histologic
examination of the lung lesion showed the presence of
Table 1 Characteristics of 5 lung transplant recipients patients with posttransplant lymphoproliferative disorder
(PTLD).
Pt. #,
age, sex
Underlying
disease
Date
of TX
Type of TX Onset of
PTLD
Immuno suppressive
treatment (dosage)
PTLD description EBV DNA
copies/
10
5PBMC
1, 29, M cystic fibrosis Dec. 2000 double-lung May 2003 Ciclosporin (350 mg/die)
Steroid (5 mg/die)
Laterocervical HL 1,760
2, 25, F cystic fibrosis Sep. 2001 double-lung May 2002 Ciclosporin (150 mg/die)
Steroid (40 mg/die)
Mediastinic large B-cells NHL < 10
3, 53, M sarcoidosis Dec. 2001 single-lung Nov. 2002 Ciclosporin (250 mg/die)
Steroid (25 mg/die)
Mediastinic large B-cells NHL < 10
4, 39, M Istiocytosis X Dec. 2004 double-lung May 2005 Ciclosporin (550 mg/die)
Steroid (5 mg/die)
thoracic localization of EBV-positive
B-cell lymphoma.
307
5, 63, M Idiopathic
pulmonary
fibrosis
Aug. 2006 double-lung Dec. 2006 Ciclosporin (300 mg/die)
Steroid (20 mg/die)
Mycophenolate mofetil
(1000 mg/die)
Single nodule in lower left lobe,
double mediastinic nodule
(at histology, no tumor markers)
751,000 EBV DNA copies/μg tissue
DNA, 8,500,000 copies/ml BAL
15, 289
TX: transplantation; PBMC: peripheral blood mononuclear cells; M: male; F: female; HL: Hodgkin lymphoma; NHL: non-Hodgkin lymphoma.
Figure 1 Kinetics of EBV DNAemia in a lung transplant
recipient developing primary EBV infection and PTLD in the
post-transplant period. The dotted line indicates EBV DNAemia
levels. The dark-grey boxes indicate treatment periods. The time of
PTLD diagnosis is indicated by the arrow.
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EBV DNA levels in PBMC (15,289 copies/1 × 10
5
PBMC), lung nodule aspirate (751,000 copies/μg tissue
DNA) and bronchoalveolar lavage (BAL) (8,500,000
copies/ml). Taken together these data were suggestive of
a pre-neoplastic EBV-associated PTLD. The patient was
submitted to significant tapering of the immune suppres-
sive regimen. One month later, a reduction in the nodule
size and EBV DNA level in PBMC (Figure 2) were
observed. On the other hand, PET analysis showed the
persistence of increased glucose uptake in mediastinic
lesions. EBV DNA determination in a lymphnode biopsy
showed 131,118,000 EBV DNA copies/0.5 ug tissue DNA
(Figure 2). Two months later, EBV DNAemia levels were
reduced by 4.9-fold (3,108 copies/1 × 10
5 PBMC) and
EBV DNA levels in BAL by 3.8-fold (2,213,300 EBV
DNA copies/ml BAL) (Figure 2). The size of the medias-
tinic nodules was reduced as well, and the intraparenchy-
mal lesion disappeared (Figure 2). Nine months after
transplantation, CT scan analysis showed the absence of
lung and mediastinal nodules, while EBV DNAemia
persisted at levels > 1,000 EBV DNA copies/1 × 10
5
PBMC (Figure 2). The patient is currently alive and well.
Tapering of immune suppression was associated with
disappearance of EBV DNAemia in the other eight
patients with EBV DNAemia levels > 1,000 copies in the
absence of radiologic findings for PTLD.
Discussion
PTLD had a prevalence of 4.5% in patients with > 3
months follow-up. This data is in agreement with
previous reports [3,18]. Despite the low number of
PTLD in our series, some conclusions can be drawn.
Although all five confirmed PTLD (3 large B-cell lym-
phomas, 1 Hodgkin lymphoma and 1 possible pre-neo-
plastic lesion) were potentially associated with EBV
infection [3], only 3 patients had detectable EBV DNAe-
mia (patient #1, 4 and 5). Thus, the two patients with
negative EBV DNAemia (patient #2 and 3) were either
carrying a B-cell PTLD not driven by EBV [5] or the
effect of EBV infection on lymphoproliferation had been
localized at the intra-thoracic level [19]. Unfortunately,
biopsies were not analyzed for EBV antigens or nucleic
acids, and neither hypothesis can be dismissed. Among
the three EBV DNAemia-positive patients with PTLD,
two showed high and one low EBV DNAemia levels.
However, EBV DNAemia could have been underesti-
mated in the latter due to lymphopenia
In conclusion: i) a combined clinical, radiological, vir-
ological and histologic approach is mandatory for the
diagnosis and management of PTLD, ii) staining for
EBV antigens and quantification of EBV DNA in biopsy
specimens should always be performed in parallel, iii)
when critically evaluated in the clinical context, EBV
DNAemia remains a useful parameter to follow-up
patients at risk for PTLD, although the present data sug-
gest that this disorder may occur also in the absence of
detectable EBV DNAemia, iv) the role of other biologic
factors remains to be elucidated.
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